Recombinant EGFR (Margetuximab Biosimilar) antibody
The Human Chimeric anti-EGFR (Margetuximab Biosimilar) antibody is suitable to detect EGFR (Margetuximab Biosimilar) in samples from Human. It has been validated for ELISA and WB.
Catalog No. ABIN7538064
$336.06
Plus shipping costs $50.00
Shipping to:
United States
Delivery in 7 to 10 Business Days
Quick Overview for Recombinant EGFR (Margetuximab Biosimilar) antibody (ABIN7538064)
Target
EGFR (Margetuximab Biosimilar)
Antibody Type
Recombinant Antibody
Reactivity
Human
Host
Human, Mouse
Clonality
Chimeric
Conjugate
This EGFR (Margetuximab Biosimilar) antibody is un-conjugated
Application
ELISA, Western Blotting (WB)
Grade
Research Grade
-
-
Expression System
- Mammalian cells
-
Purpose
- Margetuximab Biosimilar - Anti-ERBB2, EGFR2, CD340 mAb - Research Grade
-
Characteristics
- Antibody Type: IgG1-kappa
-
Purification
- Recombinant antibody expressed in mammalien cells and purified.
-
Purity
- > 85%
-
Isotype
- IgG1 kappa
-
-
-
-
Restrictions
- For Research Use only
-
-
-
Buffer
- PBS buffer PH7.5
-
Storage
- -80 °C
-
Storage Comment
- store at -80°C
-
-
- EGFR (Margetuximab Biosimilar)
-
Target Type
- Biosimilar
-
Background
- Margetuximab is an Fc-engineered human/mouse chimeric anti-HER2 monoclonal antibody of isotype IgG1 kappa . Margetuximab targets the same epitope on the HER2 extracellular domain and hass the same activity as trastuzumab. However, margetuximab has a higher affinity for both CD16A variants and a weaker one to the inhibitory CD32B Fc receptor, thereby resulting in more efficient antibody-dependent cell-mediated cytotoxicity (ADCC) and higher efficacy compared to trastuzumab.
-
CAS-No
- 1350624-75-7
Target
-
You are here:
